Clinical Trial: 19062

Trial Status: Open
Disease Type: Lymphoma
Trial ID 19062
Sponsor ID Epizyme, Inc.

Phase 3 Double-Blind, Active Controlled, 3-Stage Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma.

Principal Investigator
Mitul Gandhi, MD
4 Locations


Fairfax Office

Gainesville Office

Arlington Office

Alexandria Office

Learn More About This Trial

Other Relevant Trials
Trial ID 22041
Sponsor ID M23-362

A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)

Principal Investigator
Mitul Gandhi, MD
3 Locations
Trial ID DR-01-ONC-001
Sponsor ID Dren Bio

A Multicenter, Open-Label, First-in-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas